Skip Navigation


European Heart Journal Advance Access originally published online on November 2, 2005
European Heart Journal 2006 27(1):5-6; doi:10.1093/eurheartj/ehi624
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/1/5    most recent
ehi624v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cooper-DeHoff, R.
Right arrow Articles by Pepine, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cooper-DeHoff, R.
Right arrow Articles by Pepine, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Ranolazine is associated with cardiovascular and metabolic improvement: a win–win for patients with diabetes

Rhonda Cooper-DeHoff and Carl J. Pepine*

University of Florida, College of Medicine, Division of Cardiovascular Medicine, 1600 SW Archer Road, Gainesville, FL, USA

* Corresponding author. E-mail address: pepincj@medicine.ufl.edu

This editorial refers to ‘Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes’{dagger} by A. Timmis et al., on page 42

The first 10% of the full text of this article appears below.

Ranolazine is a novel therapeutic agent which increases exercise duration and time to angina episodes in patients with persistent chronic angina pectoris. These benefits have been observed following monotherapy and in combination with ß-blockers and calcium antagonists.1 Although the mechanism of action of ranolazine is not completely understood, emerging data suggest that ranolazine may be a potent and selective inhibitor of the late sodium current across the membrane of cardiomyocytes, which may result in improved diastolic function, microvascular flow, and cardiac efficiency without altering blood pressure, heart rate, or . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Adam D. Timmis, Bernard R. Chaitman, and Michael Crager
EHJ 2006 27: 42-48. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
J. J. Bax, B. De Bruyne, A. K. Gitt, S. Kristensen, C. Linde, D. Poldermans, F. J. Pinto, P. Ponikowski, B. D. Prendergast, E. Abagiti-Rosei, et al.
Highlights of the 2006 Scientific Sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2564 - 2574.
[Full Text] [PDF]